1. Home
  2. ALT vs RCS Comparison

ALT vs RCS Comparison

Compare ALT & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • RCS
  • Stock Information
  • Founded
  • ALT 1997
  • RCS 1994
  • Country
  • ALT United States
  • RCS United States
  • Employees
  • ALT N/A
  • RCS N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • RCS Investment Managers
  • Sector
  • ALT Health Care
  • RCS Finance
  • Exchange
  • ALT Nasdaq
  • RCS Nasdaq
  • Market Cap
  • ALT 327.4M
  • RCS 334.5M
  • IPO Year
  • ALT N/A
  • RCS N/A
  • Fundamental
  • Price
  • ALT $3.57
  • RCS $7.43
  • Analyst Decision
  • ALT Strong Buy
  • RCS
  • Analyst Count
  • ALT 6
  • RCS 0
  • Target Price
  • ALT $17.40
  • RCS N/A
  • AVG Volume (30 Days)
  • ALT 2.3M
  • RCS 141.1K
  • Earning Date
  • ALT 11-11-2025
  • RCS 01-01-0001
  • Dividend Yield
  • ALT N/A
  • RCS 10.12%
  • EPS Growth
  • ALT N/A
  • RCS N/A
  • EPS
  • ALT N/A
  • RCS N/A
  • Revenue
  • ALT $20,000.00
  • RCS N/A
  • Revenue This Year
  • ALT N/A
  • RCS N/A
  • Revenue Next Year
  • ALT $761,880.20
  • RCS N/A
  • P/E Ratio
  • ALT N/A
  • RCS N/A
  • Revenue Growth
  • ALT N/A
  • RCS N/A
  • 52 Week Low
  • ALT $2.90
  • RCS $4.51
  • 52 Week High
  • ALT $11.16
  • RCS $6.31
  • Technical
  • Relative Strength Index (RSI)
  • ALT 44.06
  • RCS 70.74
  • Support Level
  • ALT $3.54
  • RCS $7.30
  • Resistance Level
  • ALT $3.72
  • RCS $7.35
  • Average True Range (ATR)
  • ALT 0.16
  • RCS 0.05
  • MACD
  • ALT 0.01
  • RCS 0.01
  • Stochastic Oscillator
  • ALT 10.94
  • RCS 81.82

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About RCS PIMCO Strategic Income Fund Inc.

PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.

Share on Social Networks: